Advertisement
Advertisement
CAMP
CAMP4 Therapeutics Corporation Common Stock
3.89
USDSponsored
+0.30
+8.47%
Feb 06, 16:00 UTC -5
Closed
After-Market
3.85
-0.04
-1.00%
CAMP Earnings Reports
Positive Surprise Ratio
CAMP beat 2 of 5 last estimates.
40%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$306.00K
/-$0.26
Implied change from Q3 25 (Revenue/ EPS)
-61.51%
/-52.73%
Implied change from Q1 25 (Revenue/ EPS)
-64.34%
/-58.06%
CAMP4 Therapeutics Corporation Common Stock earnings per share and revenue
On Nov 06, 2025, CAMP reported earnings of -0.55 USD per share (EPS) for Q3 25, missing the estimate of -0.48 USD, resulting in a -12.73% surprise. Revenue reached 795.00 thousand, compared to an expected 530.40 thousand, with a 49.89% difference. The market reacted with a -4.49% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.26 USD, with revenue projected to reach 306.00 thousand USD, implying an decrease of -52.73% EPS, and decrease of -61.51% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were CAMP4 Therapeutics Corporation Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, CAMP4 Therapeutics Corporation Common Stock reported EPS of -$0.55, missing estimates by -12.73%, and revenue of $795.00K, 49.89% above expectations.
How did the market react to CAMP4 Therapeutics Corporation Common Stock's Q3 2025 earnings?
The stock price moved down -4.49%, changed from $4.45 before the earnings release to $4.25 the day after.
When is CAMP4 Therapeutics Corporation Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for CAMP4 Therapeutics Corporation Common Stock's next earnings report?
Based on 5
analysts, CAMP4 Therapeutics Corporation Common Stock is expected to report EPS of -$0.26 and revenue of $306.00K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement